



Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

Ebru Karasu¹, Bo Nilsson², Jörg Köhl^{3,4}, John D. Lambris⁵ and Markus Huber-Lang^{1*}

¹ Institute for Clinical and Experimental Trauma-Immunology, University Hospital of Ulm, Ulm, Germany, ² Department of Immunology, Genetics and Pathology (IGP), Laboratory C5:3, Uppsala University, Uppsala, Sweden, ³ Institute for Systemic Inflammation Research (ISEF), University of Lübeck, Lübeck, Germany, ⁴ Division of Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, United States, ⁵ Department of Pathology & Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, United States

Keywords: trauma, sepsis, hemorrhagic shock, MODS, complement activation, complement dysregulation, complement therapeutics, clinical trial

OPEN ACCESS

Approved by:

Frontiers in Immunology Editorial Office,
Frontiers Media SA, Switzerland

*Correspondence:

Markus Huber-Lang
markus.huber-lang@uniklinik-ulm.de

Specialty section:

This article was submitted to
Molecular Innate Immunity,
a section of the journal
Frontiers in Immunology

Received: 16 April 2019

Accepted: 17 April 2019

Published: 03 May 2019

Citation:

Karasu E, Nilsson B, Köhl J,
Lambris JD and Huber-Lang M (2019)
Corrigendum: Targeting Complement
Pathways in Polytrauma- and
Sepsis-Induced Multiple-Organ
Dysfunction. *Front. Immunol.* 10:994.
doi: 10.3389/fimmu.2019.00994

A Corrigendum on

Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction

by Karasu, E., Nilsson, B., Köhl, J., Lambris, J. D., and Huber-Lang, M. (2019). *Front. Immunol.* 10:543. doi: 10.3389/fimmu.2019.00543

In the original article, we neglected to include a conflict of interest statement of Prof. John D. Lambris.

JL is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors (including third-generation compstatin analogs, such as AMY-101) and is the inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. JL is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals [i.e., 4(1MeW)7W/POT-4/APL-1 and PEGylated derivatives].

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2019 Karasu, Nilsson, Köhl, Lambris and Huber-Lang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.